ACOG Menu

ACOG recommends that COVID-19 vaccines should not be withheld from pregnant individuals who meet criteria for vaccination based on ACIP-recommended priority groups.

While safety data on the use of COVID-19 vaccines in pregnancy are not currently available, there are also no data to indicate that the vaccines should be contraindicated, and no safety signals generated from Developmental and Reproductive Toxicity (DART) studies for the Pfizer-BioNtech and Moderna COVID-19 vaccines.

In the interest of allowing pregnant individuals who would otherwise be considered a priority population for vaccines approved for use under EUA to make their own decisions regarding their health, ACOG recommends that pregnant individuals should be free to make their own decision in conjunction with their clinical care team.

For more information on vaccinating pregnant women against COVID-19 see ACOG’s Practice Advisory.


The following talking points are intended to help guide risk and benefit conversations with pregnant patients:

Risk of COVID-19 Infection During Pregnancy

  • While the known absolute risk is low, pregnancy is associated with increased risk of maternal severe illness, ICU admission, mechanical ventilation and death
  • Known Increased risk of complications from COVID-19 in pregnant patients with underlying health conditions (e.g. diabetes, obesity, increasing age, and cardiovascular disease)
  • Increased risk for certain racial and ethnic populations

Safety of COVID-19 Vaccines

  • Vaccines currently available under EUA have not been tested in pregnant women. Therefore, there are no safety data specific to use in pregnancy.
    • Developmental and Reproductive Toxicology (DART) animal data is forthcoming from Pfizer-BioNtech, though a verbal report of the data did not indicate any safety signals and clinical studies in pregnant individuals are planned.
    • A combined developmental and perinatal/postnatal reproductive toxicity (DART) study of Moderna’s mRNA-1273 in rats was submitted to FDA on December 4, 2020. FDA review of this study concluded that mRNA1273 given prior to mating and during gestation periods at dose of 100 µg did not have any adverse effects on female reproduction, fetal/embryonal development, or postnatal developmental except for skeletal variations which are common and typically resolve postnatally without intervention.
  • Based on the mechanism of action of these vaccines and the demonstrated safety and efficacy in Phase II and Phase III clinical trials, it is expected that the safety and efficacy profile of the vaccine for pregnant individuals would be similar to that observed in non-pregnant individuals.
  • Injection site and systemic events (side effects) are common e.g. pain at the site of injection, fever, muscle pain, joint pain, headaches, fatigue, and other symptoms may be present after each vaccination, particularly after the second dose of vaccine.
    • Acetaminophen is recommended for pregnant women who experience fever or if desired for other side effects
    • These side effects are a normal part of the body’s reaction to the vaccine and developing antibodies to protect against COVID-19 illness
  • The mRNA vaccines are not live virus vaccines, nor do they use an adjuvant to enhance vaccine efficacy. These vaccines do not enter the nucleus of cells and do not alter human DNA in vaccine recipients. As a result, mRNA vaccines cannot cause any genetic changes.
  • On-going safety monitoring planned through many government and non-government programs
    • Encourage pregnant patients who get vaccinated to sign up for CDC’s V-SAFE safety monitoring program

Other safety programs include:

Efficacy of COVID-19 Vaccines

  • No data available in pregnancy, but likely to be similar efficacy to non-pregnant adults
  • Depending on the vaccine, up to 95% efficacy in preventing symptomatic COVID-19 disease in the first few weeks after vaccination has been reported in non-pregnant patients
  • Two doses of vaccine are necessary to achieve protection
  • May prevent severe COVID-19 disease
  • Duration of protection is unknown

Pregnant Patient’s Individual Risk Based on Circumstances

  • The level of disease activity in the community
  • The efficacy of the vaccine
  • The ability to limit exposures (eg. living space, transportation, work environment, availability of PPE)
  • The risk and potential severity of maternal disease (see above), including the effects of disease on the fetus and newborn
  • The safety of the vaccine for the pregnant patient and the fetus

Safety and Efficacy for the Newborn

  • No data available regarding protection of the newborn with maternal immunization • No vaccines are currently available for infants or young children

Special Considerations for Communities of Color

  • Access to and confidence in COVID-19 vaccines is of critical importance for all communities, but willingness to consider vaccination varies by patient context, in part due to historic and continued injustices and systemic racism that has eroded trust in some communities of color. When discussing COVID-19 vaccines with an individual who expresses concerns, it is critical to:
    • Be aware of historical and current injustices perpetuated on communities of color
    • Actively listen to and validate expressed fears and concerns
    • Continue to support patients who decide not to be vaccinated, share resources, and encourage the continued use of prevention measures

Continued Support

  • Pregnant patients who decline vaccination should be supported in their decision. Regardless of their decision to receive or not receive the vaccine, these conversations provide an opportunity to remind patients about the importance of other prevention measures such as:
    • Wearing a mask
    • Staying at least six feet away from others
    • Avoiding crowds
    • Washing hands with soap and water for 20 seconds or using hand sanitizer with at least 60% alcohol
    • Following CDC travel guidance
    • Following quarantine guidance after exposure to COVID-19
    • Following any applicable workplace guidance